Sterile Inflammation During Perioperative Care: Mechanisms, Clinical Impact, and Management Strategies

Abstract

Sterile inflammation during perioperative care represents a significant challenge in surgical and anesthetic practice, contributing to postoperative complications, delayed recovery, and increased healthcare costs. Unlike infection-driven inflammation, sterile inflammation is initiated by non-microbial triggers such as surgical trauma, ischemia-reperfusion injury, and tissue manipulation, leading to the activation of the innate immune system. This article provides a comprehensive review of the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic strategies, management approaches, recent advances, and guideline-based recommendations related to sterile inflammation in the perioperative setting, with a focus on translating scientific evidence into clinical practice for improved outcomes.

Introduction

Inflammation is a cornerstone of the body’s response to injury, yet not all inflammatory processes are initiated by pathogens. Sterile inflammation, triggered by endogenous danger signals rather than infectious agents, is increasingly recognized as a key driver of perioperative morbidity. Surgical interventions, anesthesia, mechanical ventilation, and tissue ischemia can all provoke sterile inflammatory responses that impact patient recovery, wound healing, and the risk of complications such as systemic inflammatory response syndrome (SIRS), organ dysfunction, and chronic pain. Understanding the mechanisms and clinical implications of sterile inflammation is essential for perioperative clinicians aiming to optimize patient outcomes through evidence-based strategies and targeted interventions.

Epidemiology / Disease Burden

Sterile inflammation is ubiquitous in the perioperative period, affecting a broad spectrum of surgical patients. Recent studies estimate that up to 30% of postoperative complications in major surgeries are linked to excessive inflammatory responses, many of which are sterile in origin. The burden is particularly high in cardiovascular, orthopedic, and abdominal surgeries, where tissue trauma, ischemia-reperfusion, and device implantation are common. Sterile inflammatory processes contribute to prolonged hospital stays, increased intensive care admissions, and elevated healthcare expenditures. Furthermore, specific populations—such as elderly patients, those with comorbidities, and individuals undergoing complex or prolonged procedures—are at heightened risk, underscoring the need for targeted preventive and therapeutic approaches.

Pathophysiology

The pathogenesis of sterile inflammation involves the release of damage-associated molecular patterns (DAMPs) from injured or stressed cells. These endogenous molecules—including HMGB1, ATP, uric acid, S100 proteins, and mitochondrial DNA—bind to pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome on innate immune cells. This triggers downstream signaling cascades leading to the production of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), chemokines, and reactive oxygen species (ROS). The resulting inflammatory milieu facilitates neutrophil and monocyte recruitment, endothelial activation, and increased vascular permeability. In the perioperative context, mechanical tissue injury, hypoxia, and reperfusion exacerbate these processes and may induce a systemic inflammatory response extending beyond the site of injury. The balance between pro- and anti-inflammatory mechanisms determines clinical outcomes, with dysregulated responses predisposing to organ dysfunction and impaired healing.

Risk Factors

Several factors modulate the risk and severity of sterile inflammation in the perioperative period. Key predisposing elements include the extent and duration of surgical trauma, type of anesthesia, underlying comorbidities (e.g., diabetes, obesity, cardiovascular disease), advanced age, genetic polymorphisms affecting immune regulation, and perioperative hypoxia or hypotension. Technical factors, such as the use of tourniquets, extracorporeal circulation, and prosthetic materials, also play a significant role. Furthermore, pre-existing chronic inflammation or immune dysregulation may amplify perioperative sterile inflammatory responses, highlighting the need for individualized risk assessment and tailored management strategies.

Clinical Features

The clinical manifestations of sterile inflammation are often indistinguishable from those of infection-related inflammation, posing diagnostic challenges. Common features include fever, leukocytosis, elevated acute-phase reactants (e.g., C-reactive protein, procalcitonin), and localized signs such as erythema, edema, and pain at the surgical site. Systemic manifestations may encompass tachycardia, hypotension, and, in severe cases, multi-organ dysfunction. Notably, the temporal relationship to surgery and the absence of microbiological evidence of infection are key clues. Persistent or excessive sterile inflammation may lead to poor wound healing, fibrosis, and chronic pain syndromes, underscoring its clinical relevance.

Diagnosis

Diagnosis of sterile inflammation relies on clinical assessment, laboratory parameters, and exclusion of infectious etiologies. Biomarkers such as CRP and IL-6 are elevated in both sterile and infectious inflammation, though recent studies suggest that procalcitonin may aid in differentiation, as it tends to rise more prominently in bacterial infections. Advanced diagnostics, including multiplex cytokine panels, DAMP quantification (e.g., HMGB1, mitochondrial DNA), and imaging modalities (ultrasound, CT, MRI) to exclude abscesses or collections, can provide further clarity. Nonetheless, a high index of suspicion and a multidisciplinary approach are essential, integrating clinical, laboratory, and radiological data to guide management.

Treatment & Management

Management of sterile inflammation in the perioperative setting is multifaceted and aims to minimize tissue injury, modulate immune responses, and prevent complications. Key strategies include meticulous surgical technique, judicious use of hemostatic and anti-adhesive agents, and optimization of perioperative physiological parameters (oxygenation, perfusion, glycemic control). Pharmacologic interventions, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and selective cytokine inhibitors (e.g., IL-1 or IL-6 antagonists), may be employed in selected cases, balancing anti-inflammatory efficacy against risks (infection, impaired healing). Enhanced recovery protocols, early mobilization, and nutritional support further contribute to mitigating sterile inflammatory responses. Multidisciplinary perioperative care teams, including surgeons, anesthesiologists, intensivists, and pharmacists, are pivotal in implementing individualized, evidence-based interventions.

Recent Advances / Emerging Therapies

Recent advances in the understanding of sterile inflammation have catalyzed the development of targeted therapies. Novel agents targeting DAMP signaling pathways, such as inhibitors of TLRs and the NLRP3 inflammasome, are under investigation in preclinical and early clinical studies. Biologics such as anakinra (IL-1 receptor antagonist) and tocilizumab (IL-6 receptor antagonist) have shown promise in attenuating severe inflammatory responses in specific contexts. Additionally, strategies aimed at promoting resolution of inflammation—such as specialized pro-resolving mediators (SPMs) and autophagy modulators—are emerging as potential adjuncts to perioperative care. Biomarker-guided therapy, leveraging rapid point-of-care assays for DAMPs and cytokines, holds promise for personalized risk stratification and treatment optimization.

Guideline Recommendations

Current perioperative guidelines emphasize the importance of minimizing unnecessary tissue injury, optimizing perioperative physiology, and employing evidence-based pharmacologic interventions to reduce excessive inflammation. The Enhanced Recovery After Surgery (ERAS) protocols advocate for multimodal analgesia, early mobilization, and minimization of opioid use, all of which contribute to attenuating sterile inflammatory responses. For high-risk patients, guidelines support individualized risk assessment and multidisciplinary planning. Routine use of broad-spectrum anti-inflammatory biologics is not currently recommended outside of clinical trials, given concerns regarding infection risk and incomplete evidence of benefit. Ongoing research and guideline updates are expected as new evidence emerges.

Conclusion

Sterile inflammation during perioperative care is a complex, multifactorial process with profound implications for surgical outcomes. Advances in mechanistic understanding, diagnostics, and therapeutics offer opportunities for improved risk stratification and targeted management. Multidisciplinary collaboration, adherence to evidence-based perioperative protocols, and ongoing research into emerging therapies will be pivotal in reducing the burden of sterile inflammation and enhancing patient recovery. Clinicians must remain vigilant to the nuances of differentiating sterile from infectious inflammation, ensuring that interventions are appropriately tailored to individual patient risk profiles and surgical contexts.